Weight Management
Conditions
Brief summary
Lactobacillus gasseri BNR17™ has shown promise in several pre-clinical and randomized controlled clinical trials for weight management outcomes. The current randomized, double-blind, placebo-controlled, parallel-arm trial will further assess L. gasseri BNR17™ on body composition and weight management, and in a study population that is distinct to prior randomized controlled trials on the strain. The study will recruit 126 overweight adult participants who will be randomly assigned to consume L. gasseri BNR17™ or placebo once daily for 12 weeks.
Interventions
DIETARY_SUPPLEMENTLactobacillus gasseri BNR17™ capsule
Once per day (QD), 12 weeks
OTHERPlacebo capsule
Once per day (QD), 12 weeks
Sponsors
UAS Labs LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
25 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Written informed consent; * Aged between 25 and 65 years inclusive; * Body mass index between 25.0 to 29.9 Kg/m2, inclusive; * Waist-hip ratio of ≥0.91 for males and ≥0.81 for females; * Sedentary lifestyle, exercising ≤2 times/week; * Good general health, as determined by the investigator; * Willing to consume the investigational product daily for the duration of the study; * Outside the healthy parameters of visceral adipose tissue, defined as 762 cm3 for males and 256 cm3 for females.
Exclusion criteria
* Females who are pregnant, lactating or wish to become pregnant during the study; * Participant regularly takes probiotic supplements, or has within the 4-weeks prior to randomisation or plans to during the study; * Participant is hypersensitive to any of the components of the investigational product; * Participant is severely immuno-compromised (HIV positive, transplant patient, on antirejection medications, on a steroid for \>30 days, or has underwent chemotherapy or radiotherapy within the last year); * Participant has Type 1 or Type 2 Diabetes Mellitus; * Participant has a history of bariatric surgery; * Participant has taken anti-obesity medication or supplements in the 12-weeks prior to randomisation or plans to during the study; * Participant is actively or has recently (3 months prior to randomisation) participated in a weight loss program or weight change of 3 kg during the past 3 months; * Participant has a life-threatening illness; * Participant is on a glucose lowering medication, anti-psychotic drugs or any medication that the investigator determines could impact the results of the study; participant has commenced use, within 3-months of randomisation, anti-hypertensive drugs, anti-depressive drugs, statin or any other medication that the investigator determines could impact the results of the study; * Participant has a history of co-existing gastrointestinal, and/or gynecological, and/or urologic pathology (e.g. colon cancer, colitis, Crohn's Disease, Celiac, Endometriosis, prostate cancer) or lactose intolerance; * Participant has a recent history of drug and/or alcohol abuse at the time of enrolment; * Participant is currently, or planning to participate in another study during the study period; * Participant has a history of non-compliance; * Participant has taken antibiotics in the 12-weeks prior to randomisation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Absolute change from baseline to week 12 in visceral adipose tissue (VAT) | 12 weeks | VAT will be assessed using dual energy x-ray absorptiometry |
Secondary
| Measure | Time frame |
|---|---|
| Absolute change from baseline to week 12 in body weight | 12 weeks |
| Absolute change from baseline to week 12 in waist circumference | 12 weeks |
| Absolute change from baseline to week 12 in waist-to-hip ratio | 12 weeks |
| Absolute change from baseline to week 12 in blood glucose | 12 weeks |
| Absolute change from baseline to week 12 in HbA1c | 12 weeks |
| Absolute change from baseline to week 12 in blood insulin | 12 weeks |
| Absolute change from baseline to week 12 in hs-CRP | 12 weeks |
| Absolute change from baseline to week 12 in total fat mass | 12 weeks |
| Absolute change from baseline to week 12 in total lean mass | 12 weeks |
Other
| Measure | Time frame |
|---|---|
| Safety blood profile (clinical chemistry and full blood count) | 12 weeks |
| Vitals (systolic blood pressure, diastolic blood pressure, heart rate and temperature) | 12 weeks |
| Adverse events (frequency, severity and relatedness) | 12 weeks |
| Gastrointestinal symptom rating scale | 12 weeks |
Countries
Ireland
Outcome results
None listed